HYPEROXIA: Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications?

Sponsor
Örebro University, Sweden (Other)
Overall Status
Completed
CT.gov ID
NCT02562781
Collaborator
(none)
184
2
2
74
92
1.2

Study Details

Study Description

Brief Summary

Patients undergoing vascular surgery are at a significantly high risk of perioperative cardiovascular, cerebral and renal events compared to those undergoing non-vascular surgery. This could be because of co-morbidities that are common in this patient group. Additionally, smoking, which is common in this population, may be a contributing factor.

Oxygen therapy has been used for decades in order to reduce the risk of myocardial infarction and stroke in patients undergoing vascular surgery and pre-existing co-morbidities in the belief that increased inspired oxygen increases oxygen delivery to tissues, thereby reducing the risk for hypoxia and cell death. However, several studies published recently have questioned the routine use of high inspired oxygen concentration (hyperoxia) to improve oxygen delivery, specifically in the neonatal period but possibly even following myocardial infarction. This could be explained by the fact that increasing inspired concentrations of oxygen cause vasoconstriction in cerebral and coronary arteries, thereby reducing blood flow. Additionally, increased oxygen causes excessive production of reactive oxygen species (ROS), and repercussion injury from oxidative stress. The latter can lead to apoptosis (cell death) in myocardial or cerebral neurons. Despite the high risks of administering oxygen when not needed, it is routinely used in hospitals all over the world without a doctors prescription.

This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Oxygen is probably one of the commonest "non-prescription" drug used in the hospital and its advantage in several situations including carbon monoxide poisoning, central hypoxia and prior to planned intubation in an acute situation are today well-established and commonly used. Oxygen has been frowned upon in the resuscitation of newborn babies because of the risk of retrolental hypoplasia, now well accepted and adopted in clinical practice. Oxygen has also been traditionally used to increase oxygen carrying capacity in patients presenting with an acute coronary syndrome (ACS), to reduce surgical site infections (SSI), to ensure adequate oxygen delivery to tissues in unconscious patients, during cardiac surgery and for postoperative management, specifically after major surgery. Thus, deliberate use of high inspiratory oxygen concentrations (e.g., 80% or above) is recommended in the treatment of specific intoxications, such as with carbon monoxide or cyanide, wherein hyperbaric oxygen should also be considered. In addition, a high oxygen fraction has been suggested to prevent adverse outcomes after surgery and anesthesia, including a reduction in wound infections and postoperative nausea and vomiting (PONV). In critically ill patients, oxygen delivery to the tissues is often compromised, and supplemental oxygen (e.g., face mask with 10 L oxygen per min) is commonly administered to patients with pneumonia, sepsis, acute coronary syndrome, or stroke - in fact, it is estimated that oxygen is given during transport in approximately one-third of all ambulance journeys.

Several reports published recently have questioned many of the "routine" uses of oxygen and some evidence even seems to point towards negative outcomes in some of these conditions. Specifically, excessive oxygen is likely to do more harm than good in the neonatal period, following cardio-pulmonary resuscitation and likely following acute myocardial infarction. Prospective, randomised studies on this important use of oxygen in the preoperative string are, however, lacking in the literature and in view of theoretical risks for hyperoxemia to several organs, the routine use of high oxygen fractions during the peri-operative phase can be questioned.

This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).

Study Design

Study Type:
Interventional
Actual Enrollment :
184 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? A Randomised, Prospective Study in Patients Undergoing Vascular Surgery
Study Start Date :
Nov 1, 2014
Actual Primary Completion Date :
Dec 1, 2020
Actual Study Completion Date :
Jan 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Supplemental Oxygen

Inspired oxygen fraction > 0.5 and SpO2 = 98-100%

Drug: Oxygen
Oxygen in sufficient quantity to maintain SpO2 > 98%
Other Names:
  • Medical oxygen
  • Other: Air
    Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
    Other Names:
  • Medical Air
  • Experimental: Air or supplemental oxygen

    Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%

    Drug: Oxygen
    Oxygen in sufficient quantity to maintain SpO2 > 98%
    Other Names:
  • Medical oxygen
  • Other: Air
    Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
    Other Names:
  • Medical Air
  • Outcome Measures

    Primary Outcome Measures

    1. Composite morbidity [0 - 1 month postoperatively]

      Major complications such as MACE, TIA/stroke/renal insufficiency/POCD etc

    Secondary Outcome Measures

    1. Long term outcome (Major complications) [1 month to 1 year postoperatively]

      Major complications

    2. Specific outcomes (Major adverse cardiac events (MACE)) [0 - 1 year postoperatively]

      Major adverse cardiac events (MACE)

    3. Specific outcomes (TIA or stroke) [0 - 1 year postoperatively]

      TIA or stroke

    4. Specific outcomes (renal insufficiency including dialysis or renal failure) [0 - 1 year postoperatively]

      renal insufficiency including dialysis or renal failure

    Other Outcome Measures

    1. Complication (Re-operation or bleeding) [0 - 30 days postoperatively]

      Re-operation or bleeding

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients undergoing elective vascular surgery (peripheral or aortic surgery),

    • No language or cognitive disability

    • Written, informed consent

    Exclusion Criteria:
    • Patients with COPD/other lung diseases that require preoperative oxygen therapy

    • Patients undergoing carotid artery surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Örebro Sweden 701 85
    2 Örebro University Hospital Örebro Sweden 70185

    Sponsors and Collaborators

    • Örebro University, Sweden

    Investigators

    • Principal Investigator: Anil Gupta, MD, PhD, Örebro University, Sweden

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anil Gupta, Associate Professor, Örebro University, Sweden
    ClinicalTrials.gov Identifier:
    NCT02562781
    Other Study ID Numbers:
    • ÖrebroU
    First Posted:
    Sep 29, 2015
    Last Update Posted:
    Mar 4, 2021
    Last Verified:
    Mar 1, 2021
    Keywords provided by Anil Gupta, Associate Professor, Örebro University, Sweden
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 4, 2021